Synerkine Pharma B.V. focuses on development of novel fusion proteins, called Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Galileiweg 8, Leiden,2333 Bd,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://synerkinepharma.com
- Keywords
- Manager jobs.
- HQ
- Leiden
Synerkine Pharma Questions
Synerkine Pharma's website is https://synerkinepharma.com
Synerkine Pharma's LinkedIn profile is https://nl.linkedin.com/company/synerkine-pharma
Synerkine Pharma has
9 employees.
View email and phone details for 9
employees at Synerkine Pharma.
Synerkine Pharma's industry is
Biotechnology Research
Synerkine Pharma's top competitors are
Scenic Biotech,
Northx Biologics,
Leyden Labs,
Genmab,
Amarna Therapeutics,
Future Genomics Technologies,
Single Cell Discoveries,
Targed Biopharmaceuticals,
Vectory,
Mendus Ab.
Synerkine Pharma's categories are Biotechnology Research
Synerkine Pharma's founding year is 2018
